BMY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BMY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Bristol-Myers Squibb Co's annualized Gross Profit for the quarter that ended in Mar. 2024 was $35,732 Mil. Bristol-Myers Squibb Co's average Total Assets over the quarter that ended in Mar. 2024 was $97,095 Mil. Therefore, Bristol-Myers Squibb Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 36.80%.
The historical data trend for Bristol-Myers Squibb Co's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Gross-Profit-to-Asset % | Get a 7-Day Free Trial |
![]() |
![]() |
21.91 | 24.75 | 32.00 | 34.95 | 35.75 |
Bristol-Myers Squibb Co Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Gross-Profit-to-Asset % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
36.72 | 35.58 | 36.63 | 37.47 | 36.80 |
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's Gross-Profit-to-Asset % falls into.
Bristol-Myers Squibb Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (A: Dec. 2023 ) | / | ( (Total Assets (A: Dec. 2022 ) | + | Total Assets (A: Dec. 2023 )) | / count ) |
= | 34313 | / | ( (96820 | + | 95159) | / 2 ) | |
= | 34313 | / | 95989.5 | ||||
= | 35.75 % |
Bristol-Myers Squibb Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:
Gross-Profit-to-Asset % | = | Gross Profit (Q: Mar. 2024 ) | / | ( (Total Assets (Q: Dec. 2023 ) | + | Total Assets (Q: Mar. 2024 )) | / count ) |
= | 35732 | / | ( (95159 | + | 99031) | / 2 ) | |
= | 35732 | / | 97095 | ||||
= | 36.80 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.
Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S. Boerner | officer: EVP, Chief Commercial Officer | 21823 30TH DRIVE S, BOTHELL WA 98021 |
Samuels Theodore R. Ii | director | 1990 E. GRAND AVE., EL SEGUNDO CA 90245 |
Cari Gallman | officer: EVP, Corporate Affairs | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Ann Powell Judge | officer: SVP, Human Resources | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Robert M Plenge | officer: EVP, Chief Research Officer | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Rupert Vessey | officer: Pres., Research & Early Dev. | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Adam Lenkowsky | officer: EVP, Chief Commercial Officer | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Giovanni Caforio | officer: EVP & Chief Commercial Officer | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
David V Elkins | officer: EVP, Chief Financial Officer | C/O BECTON, DICKINSON AND COMPANY, 1 BECTON DRIVE, FRANKLIN LAKES NJ 07417 |
Deepak Bhatt | director | BRISTOL MYERS SQUIBB, 430 E. 29TH STREET, 14TH FLOOR, NEW YORK NY 10016 |
Sandra Leung | officer: Vice President and Secretary | C/O BRISTOL MYERS SQUIBB CO, 345 PARK AVE, NEW YORK NY 10164 |
Sharon Greenlees | officer: SVP & Controller | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Karin Shanahan | officer: EVP, Glob. Prod. Dev. & Supply | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Gregory Scott Meyers | officer: EVP, Chief Digital & Tech Off. | BRISTOL MYERS SQUIBB, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
Autenried Paul Von | officer: SVP, Enterp. Services & CIO | BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.